Author: jlolds

Native Angeleno, professor of Neuroscience and Public Policy at George Mason University

Reviewing grants

I’m submerged at the moment in a virtual pile of grant proposals that are stored in my iPad. They are collectively very interesting, but also have a unique ability to suck up all of one’s available time. How far away are we from Strong AI to review grants?

Luck and science success

There’s an apocryphal story about how my Dad and Peter Milner discovered the phenomenon of reinforcing self-stimulation (“the pleasure center”)–the stimulating electrode was in fact bent and went into the medial forebrain bundle quite by accident. That was the luck. The scientific success came from recognizing the resultant behavior and following up on the histological data to see where the stimulating electrode actually went.

As far as I know, the above story is true.

But the combination of luck and good science are behind many significant discoveries. The key is to work hard enough to generate your own luck and then to be imaginative to recognize a lucky success for what it is with subsequent follow up experiments.

That’s the best advice I can give for a young experimentalist these days.

State of the Institute Talk

Tomorrow’s regular Monday seminar here at Krasnow is my annual report on the state of the institute. To telegraph, we face four main challenges going forward:

First, we have to position the Institute to adapt to what will surely be a changing federal R&D environment in the near future.

Second, we need to build on our critical mass of tenure-line faculty members. Both of our academic departments need to grow to adequately support their programs and to use our new research infrastructure effectively.

Third, we need to think internationally, both in terms of future scientific collaborations, but also in terms of funding of our scientific research.

And finally, we need to continue to actively fund raise from our stakeholders and donors to support Phase III and the synergies that will come from having all of our faculty, students and staff under one roof.

I’m looking forward to my talk…

A sad tale of scientific bad-behavior…

From The Economist, here.  From the article, it all started this way:

ANIL POTTI, Joseph Nevins and their colleagues at Duke University in Durham, North Carolina, garnered widespread attention in 2006. They reported in the New England Journal of Medicine that they could predict the course of a patient’s lung cancer using devices called expression arrays, which log the activity patterns of thousands of genes in a sample of tissue as a colourful picture (see above). A few months later, they wrote in Nature Medicine that they had developed a similar technique which used gene expression in laboratory cultures of cancer cells, known as cell lines, to predict which chemotherapy would be most effective for an individual patient suffering from lung, breast or ovarian cancer.

What follows is really sad.

The tenor on neurotechnology…

From the NeuroInsights meeting in Helsinki, the mood seems to be quite pessimistic on the industry–as in, how could one possibly make money off it. I think at least part of this is reflective of the on-going recession (especially here in Europe).

There’s another meme going on here: that the EU regulatory environment is much better for neurotech than the corresponding one in the US.

 Let’s see if there’s some deal making this evening….